Document Detail


Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.
MedLine Citation:
PMID:  18279770     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We describe the baseline characteristics of subjects randomised in the largest placebo-controlled, morbidity-mortality trial to date in patients with heart failure and preserved ejection fraction - the irbesartan in heart failure with preserved systolic function trial (I-PRESERVE).
METHODS AND RESULTS: 4133 patients with a mean age of 72 years (a third were 75 years or older) were randomised and 60% were women. The mean (SD) LVEF was 59 (9)% and almost 80% of patients were in NYHA Class III or IV. Approximately 80% of patients were also overweight or obese. Heart failure was reported by investigators to have a hypertensive aetiology in 64% of patients. Prior myocardial infarction was relatively uncommon (24%), as was coronary revascularisation (13%). Atrial fibrillation and diabetes each occurred in between a quarter and a third of patients. The following treatments were used at baseline: diuretic 83%, beta-blocker 59%, calcium channel blocker 40%, ACE inhibitor 25%, spironolactone 15% and digoxin 14%.
CONCLUSIONS: Patients in I-PRESERVE are broadly representative of those seen in epidemiological studies and, because of this, the results of this trial should be generally applicable to "real world" patients with heart failure and preserved ejection fraction.
Authors:
John J V McMurray; Peter E Carson; Michel Komajda; Robert McKelvie; Michael R Zile; Agata Ptaszynska; Christoph Staiger; J Mark Donovan; Barry M Massie
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of heart failure     Volume:  10     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-18     Completed Date:  2008-05-28     Revised Date:  2011-06-08    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  149-56     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Western Infirmary, Glasgow, and Faculty of Medicine, University of Glasgow, Scotland, UK. jmcmurray@bio.gla.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Atrial Fibrillation / epidemiology
Biphenyl Compounds / therapeutic use
Body Mass Index
Diabetic Angiopathies / epidemiology
Female
Heart Failure / drug therapy,  physiopathology*
Humans
Male
Stroke Volume*
Tetrazoles / therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Biphenyl Compounds; 0/Tetrazoles; 138402-11-6/irbesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gender related differences in patients presenting with acute heart failure. Results from EuroHeart F...
Next Document:  Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulatio...